{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:48:33Z","timestamp":1759513713743},"reference-count":16,"publisher":"Akademiai Kiado Zrt.","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>The choice of treatment of patients with hypertension should not be based solely on the blood pressure value, because the risk of cardiovascular diseases are influenced by the presence and magnitude of other risk factors, too. The presence of a metabolic disease (diabetes mellitus, metabolic syndrome) itself categorizes the patient as a high risk individual. In such cases the use of combined treatment is usually considered. For example, in case of hypertension aggraviated by left ventricular dysfunction, ischaemic heart disease or cardiac insufficiency, \u03b2-blocker treatment is usually included in the combination of the first setting. Orv. Hetil., 2015, 156(16), 623\u2013625.<\/jats:p>","DOI":"10.1556\/oh.2015.30146","type":"journal-article","created":{"date-parts":[[2015,4,12]],"date-time":"2015-04-12T01:01:12Z","timestamp":1428800472000},"page":"623-625","source":"Crossref","is-referenced-by-count":1,"title":["The role of \u03b2-blockers in patients with metabolic syndrome and hypertension"],"prefix":"10.1556","volume":"156","author":[{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"first","affiliation":[{"name":"Petz Alad\u00e1r Megyei Oktat\u00f3 K\u00f3rh\u00e1z Kardiol\u00f3giai Oszt\u00e1ly Gy\u0151r Vasv\u00e1ri P\u00e1l \u00fat 2\u20134. 9024"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"<i>Mancia, G., Fagard, R., Narkiewicz, K., et al.:<\/i> 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2013, <i>34<\/i>(28), 2159\u20132219.","DOI":"10.1093\/eurheartj\/eht151"},{"key":"2","unstructured":"<i>Kiss, I.:<\/i> Professional and organizational guidelines of treatment of hypertension in adults and children. [A hypertoniabetegs\u00e9g feln\u0151ttkori \u00e9s gyermekkori kezel\u00e9s\u00e9nek szakmai \u00e9s szervezeti ir\u00e1nyelvei.] Hypertonia \u00e9s Nephrologia, 2009, <i>13,<\/i> 89\u2013167. [Hungarian]"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Shin, J. A., Lee, J. H., Lim, S. Y., et al.:<\/i> Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J. Diabetes Investig., 2013, <i>4<\/i>(4), 334\u2013343.","DOI":"10.1111\/jdi.12075"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Isomaa, B., Almgren, P., Tuomi, T., et al.:<\/i> Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, <i>24<\/i>(4), 683\u2013689.","DOI":"10.2337\/diacare.24.4.683"},{"key":"5","doi-asserted-by":"crossref","unstructured":"<i>D\u00e9zsi, C. A.:<\/i> Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A critical review of the evidence. Am. J. Cardiovasc. Drugs, 2014, <i>14<\/i>(3), 167\u2013173.","DOI":"10.1007\/s40256-013-0058-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>Bangalore, S., Parkar, S., Grossman, E., et al.:<\/i> Meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol., 2007, <i>100<\/i>(8), 1254\u20131262.","DOI":"10.1016\/j.amjcard.2007.05.057"},{"key":"7","unstructured":"<i>D\u00e9zsi, C. A.:<\/i> On what basis do we choose beta-blocker? [Mi alapj\u00e1n v\u00e1lasszunk b\u00e9ta-blokkol\u00f3t?] Cardiologia Hungarica, 2012, <i>42<\/i>(5), 317\u2013321. [Hungarian]"},{"key":"8","doi-asserted-by":"crossref","unstructured":"<i>Agabiti Rosei, E., Rizzoni, D.:<\/i> Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs, 2007, <i>67<\/i>(8), 1097\u20131107.","DOI":"10.2165\/00003495-200767080-00001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Ayers, K., Byrne, L. M., DeMatteo, A., et al.:<\/i> Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension, 2012, <i>59<\/i>(4), 893\u2013898.","DOI":"10.1161\/HYPERTENSIONAHA.111.189589"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Toblli, J. E., DiGennaro, F., Giani, J. F., et al.:<\/i> Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc. Health Risk Manag., 2012, <i>8,<\/i> 151\u2013160.","DOI":"10.2147\/VHRM.S20669"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Janssens, W. J., van de Water, A., Xhonnheux, R., et al.:<\/i> Nebivolol is devoid of intrinsic sympathomimetic activity. Eur. J. Pharmacol., 1989, <i>159<\/i>(1), 89\u201395.","DOI":"10.1016\/0014-2999(89)90047-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Kamp, O., Sieswerda, G. T., Visser, C. A.:<\/i> Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. J. Cardiol., 2003, <i>92<\/i>(3), 344\u2013348.","DOI":"10.1016\/S0002-9149(03)00645-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Conti, V., Russomanno, G., Corbi, G., et al.:<\/i> Adrenoreceptors and nitric oxide in the cardiovascular system. Front. Physiol, 2013, <i>4,<\/i> 321.","DOI":"10.3389\/fphys.2013.00321"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Roman, M. J., Devereux, R. B., Kizer, J. R., et al.:<\/i> High central pulse pressure is independently associated with adverse cardiovascular outcome: the Strong Heart Study. J. Am. Coll. Cardiol., 2009, <i>54<\/i>(18), 1730\u20131734.","DOI":"10.1016\/j.jacc.2009.05.070"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Kampus, P., Serg, M., Kals, J., et al.:<\/i> Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension, 2011, <i>57<\/i>(6), 1122\u20131128.","DOI":"10.1161\/HYPERTENSIONAHA.110.155507"},{"key":"16","doi-asserted-by":"crossref","unstructured":"<i>Kotecha, D., Holmes, J., Krum, H., et al.:<\/i> Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, 2014, <i>384<\/i>(9961), 2235\u20132243.","DOI":"10.1016\/S0140-6736(14)61373-8"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2015.30146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:57:15Z","timestamp":1590141435000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2015.30146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":16,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1556\/OH.2015.30146"],"URL":"https:\/\/doi.org\/10.1556\/oh.2015.30146","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}